local_hospital

Evangelisches Klinikum Bethel gGmbH

Address
lock Available on a paid plan

Hemic and Lymphatic Diseases

At Evangelisches Klinikum Bethel gGmbH in Bielefeld, pediatric research in hematologic and lymphatic diseases focuses on improving outcomes for children and adolescents with cancers such as myeloid leukemia in children with Down syndrome, mature aggressive B-cell lymphoma and leukemia, and standard-risk ALK-positive anaplastic large cell lymphoma. These studies are designed to refine treatment approaches, strengthen survival results, and better understand long-term disease control.

  • Myeloid leukemia in children with Down syndrome – evaluating treatment effectiveness and survival
  • Mature aggressive B-cell lymphoma and leukemia – testing ways to improve event-free survival and immune recovery
  • ALK-positive anaplastic large cell lymphoma – assessing whether simpler therapy can still maintain strong cure rates

This area combines pediatric oncology and blood cancer research with a clear goal of making therapies safer and more effective for young patients.

Neoplasms

The site is also active in solid tumor and broader neoplasm research, with trials addressing Ewing sarcoma, malignant extracranial germ cell tumours, medulloblastoma, high-risk neuroblastoma, and stage IV childhood renal tumour. The main focus is on testing better treatment strategies, improving response rates, and preserving long-term outcomes in children and adolescents with cancer.

  • Ewing sarcoma – studying treatment optimization to improve event-free survival
  • Malignant extracranial germ cell tumours – comparing therapies to maintain cure rates while reducing treatment burden
  • Medulloblastoma – evaluating risk-adapted approaches for different biological subgroups
  • High-risk neuroblastoma – investigating intensified and immune-based strategies for better disease control
  • Childhood renal tumour with metastasis – assessing preoperative treatment effectiveness in advanced disease

Together, these trials reflect a strong emphasis on pediatric cancer care, with research aimed at making treatment more precise and more effective for difficult-to-treat tumors.

Nutritional and Metabolic Diseases

Research in nutritional and metabolic diseases includes studies in type 1 diabetes mellitus, with attention to long-term safety and disease management in young people. At Evangelisches Klinikum Bethel gGmbH, this work supports better understanding of immune-related treatment effects and the ongoing care needs of children and adolescents living with chronic metabolic disease.

  • Type 1 diabetes mellitus – evaluating long-term safety of a therapy aimed at preserving disease control

The research contributes to endocrinology and pediatric chronic disease management, with a focus on safer, more durable treatment strategies.

Respiratory Tract Diseases

In respiratory tract disease research, the site studies conditions such as respiratory distress syndrome in preterm infants and severe asthma exacerbations in preschool children. These trials aim to improve breathing outcomes early in life and reduce serious flare-ups in young children with asthma.

  • Respiratory distress syndrome in preterm infants – testing ways to improve longer-term lung function
  • Severe asthma exacerbations in preschool asthma – evaluating add-on treatment to prevent serious attacks

This area highlights neonatal care and pediatric pulmonology, with research centered on better symptom prevention and healthier lung development.

Site Overview

assignment
14
connected trials
corporate_fare
10
sponsors
science
44
IMPs

Activity Indicator

Last 6 months

2
Trials started
New activity detected vs previous period.
0
Trials started 6–12 months ago
14
Total trials linked
Highly Active
trending_upGrowing+100%
1
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 2 of 4 therapeutic areas and 15 of 44 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
10
Sponsors (total)
10
Active sponsors
6

Sponsor Network

Top 6 by active trials.

lock +5 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 2 161 other sites in Germany

description
Trial volume
14
Outperforms 87% of sites
public
Therapeutic diversity
4areas
Outperforms 86% of sites
groups
Sponsor diversity
10sponsors
Outperforms 87% of sites

Therapeutic Area Benchmark — Germany

Select a therapeutic area to compare against other sites in Germany.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Germany

Market Share

Country: Germany

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Evangelisches Klinikum Bethel gGmbH

lock Showing 1 of 14 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
Efficacy and Safety of Tiotropium Bromide Monohydrate in Preventing Severe Asthma Exacerbations in Preschool Children with Partial and Uncontrolled AsthmaGoethe University FrankfurtPhase IIINot RecruitingFeb 2022Apr 2025

IMP list

lock Showing 1 of 44 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Etoposide5Unknown2017-07-122024-11-21

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.